Nevro Announces Participation In Upcoming Investor Conferences
Nevro Corp. (NYSE: NVRO), based in Redwood City, California, announced its participation in two upcoming investor conferences. On September 9, 2022, CFO Rod MacLeod will present at the Wells Fargo Healthcare Conference at 9:10 am ET in Boston, MA. The following week, on September 12, 2022, he will present at the Morgan Stanley 20th Annual Global Healthcare Conference at 9:55 am ET in New York, NY. Webcasts of both events will be available on Nevro's website. Nevro specializes in innovative solutions for chronic pain, with its proprietary 10 kHz Therapy benefiting over 80,000 patients globally.
- None.
- None.
REDWOOD CITY, Calif., Aug. 9, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that it is participating in the following investor conferences:
- On September 9, 2022, Rod MacLeod, Chief Financial Officer, will present at the Wells Fargo Healthcare Conference at 9:10 am Eastern Time at the Encore Boston Harbor Hotel in Boston, MA.
- On September 12, 2022, Rod MacLeod, Chief Financial Officer, will present at the Morgan Stanley 20th Annual Global Healthcare Conference at 9:55 am Eastern Time at the Sheraton New York Hotel in New York, NY.
A webcast for these events, as well as an archived recording, will be available in the Investors section of Nevro's website at www.nevro.com.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 80,000 patients globally.
Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic trunk and limb pain and painful diabetic neuropathy. Senza®, Senza II®, and Senza Omnia™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy. Nevro's unique support services provide every patient with an HFX Coach™ throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.
Senza, Senza II, Senza Omnia, HFX, HXF Coach, HFX Cloud, HFX Connect, Nevro and the Nevro logo are trademarks of Nevro Corp.
To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.
Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Chief Corp Communications and Investor Relations Officer
650-433-3247 | julie.dewey@nevro.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-announces-participation-in-upcoming-investor-conferences-301601857.html
SOURCE Nevro Corp.
FAQ
What conferences will Nevro participate in on September 9 and 12, 2022?
Who is presenting Nevro's information at the upcoming conferences?
Where are the Wells Fargo and Morgan Stanley conferences being held?
What time will Nevro's CFO present at the Wells Fargo Healthcare Conference?
Where can I find the webcast for Nevro's conference presentations?
What innovative solutions does Nevro offer for chronic pain?
